From: Prescription Sequence Symmetry Analysis (PSSA) to assess prescribing cascades: a step-by-step guide
1 | Specify at which medication class level the index medication will be collected. Is the ADR caused by a group of medication or an individual medication? |
2 | Specify at which medication class level the marker medication will be collected. Is the ADR treated by one individual medication or a medication group or with medication from different medication groups? |
3 | Specify which combination products will be included in the data collection for the index and/or marker medication. |
4 | Specify how it will be ensured that the patients have sufficient history and follow-up data. Which additional data will be used to ascertain continuous enrollment? |
5 | Consider characteristics of the ADR, such as the possible dose-relatedness of the ADR and when the ADR generally occurs to inform decisions on subgroup analysis and time windows. |
6 | Consider patient characteristics that might influence the development of the ADR (e.g. sex, age or comorbidities) to inform patient inclusion or subgroup analysis. |
7 | Consider co-medication that might influence the development of the ADR to inform patient inclusion or subgroup analysis. |